Evidence map›Paper›PMID 34061951›Full record

ArticleInvestigative ophthalmology & visual science2021

Ex Vivo-Induced Bone Marrow-Derived Myeloid Suppressor Cells Prevent Corneal Allograft Rejection in Mice.

Jun Zhu, Takenori Inomata, Keiichi Fujimoto, Koichiro Uchida, Kenta Fujio, Ken Nagino, Maria Miura, Naoko Negishi, Yuichi Okumura, Yasutsugu Akasaki and 7 more

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Jun ZhuDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takenori InomataDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Keiichi FujimotoDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Koichiro UchidaAtopy Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Kenta FujioDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Ken NaginoDepartment of Hospital Administration, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Maria MiuraDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Naoko NegishiAtopy Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Yuichi OkumuraDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Yasutsugu AkasakiDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Kunihiko HirosawaDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Mizu KuwaharaDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Atsuko EguchiDepartment of Hospital Administration, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Hurramhon ShokirovaDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Ai YanagawaDepartment of Digital Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Akie Midorikawa-InomataDepartment of Hospital Administration, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Akira MurakamiDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Juntendo University · JPJuntendo University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the effects of ex vivo-induced bone marrow myeloid-derived suppressor cells (BM-MDSCs) on allogeneic immune responses in corneal transplantation. Methods: Bone marrow cells from C57BL/6J (B6) mice were cultured with IL-6 and GM-CSF for four days. The ex vivo induction of the BM-MDSCs was assessed using flow cytometry, inducible nitric oxide synthase (iNOS) mRNA expression using reverse transcription-quantitative polymerase chain reaction, and nitric oxide (NO) production in allogeneic stimulation. T-cell proliferation and regulatory T-cell (Treg) expansion were investigated on allogeneic stimulation in the presence of ex vivo-induced BM-MDSCs. IFN-γ, IL-2, IL-10, and TGF-β1 protein levels were measured using enzyme-linked immunosorbent assays. After subconjunctival injection of ex vivo-induced BM-MDSCs, the migration of the BM-MDSCs into corneal grafts, allogeneic corneal graft survival, neovascularization, and lymphangiogenesis were assessed using flow cytometry, slit-lamp microscopy, and immunohistochemistry. Results: The combination of GM-CSF and IL-6 significantly induced BM-MDSCs with increased iNos mRNA expression. The ex vivo-induced BM-MDSCs promoted NO release in allogeneic stimulation in vitro. The ex vivo-induced BM-MDSCs inhibited T-cell proliferation and promoted Treg expansion. Decreased IFN-γ and increased IL-2, IL-10, and TGF-β1 production was observed in coculture of ex vivo-induced BM-MDSCs. Injected ex vivo-induced BM-MDSCs were confirmed to migrate into the grafts. The injected BM-MDSCs also prolonged corneal graft survival and prevented angiogenesis and lymphangiogenesis. Conclusions: The ex vivo-induced BM-MDSCs have suppressive effects on allogeneic immune responses and prolong corneal allograft survival via the iNOS pathway, indicating that they may be a potential therapeutic tool for corneal transplantation.

Indexed as

Corneal TransplantationAdoptive TransferAnimalsBone MarrowCorneal DiseasesDrug DiscoveryGraft RejectionGraft SurvivalImmunity, CellularMiceMice, Inbred C57BLMyeloid-Derived Suppressor CellsNitric Oxide Synthase Type IISuppressor Factors, ImmunologicT-Lymphocytes, RegulatoryTransplantation, HomologousNitric Oxide Synthase Type IINos2 protein, mousesoluble immune-response suppressor, bone marrowSuppressor Factors, Immunologic

Identifiers

PMID34061951
PMCPMC8185403
OpenAlexW3165350166

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.